| Debt
|
|
|
|
|
|
|
1. BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its wholly-owned subsidiary, Greatbatch Ltd. (collectively “Greatbatch” or the “Company”), for the periods presented. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. The December 30, 2011 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. For further information, refer to the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended December 30, 2011. The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. For 52-week years, each quarter contains 13 weeks. The first quarter of 2012 and 2011 each contained 13 weeks and ended on March 30, and April 1, respectively.
|
2. ACQUISITIONS
NeuroNexus Technologies, Inc.
On February 16, 2012, the Company purchased all of the outstanding common stock of NeuroNexus Technologies, Inc. (“NeuroNexus”) headquartered in Ann Arbor, MI. NeuroNexus is an active implantable medical device design firm specializing in developing and commercializing high-value neural interface technology, components and systems for neuroscience and clinical markets. NeuroNexus has an extensive intellectual property portfolio, core technologies and capabilities to support the development and manufacturing of neural interface devices across a wide range of applications including neuromodulation, sensing, optical stimulation and targeted drug delivery.
This transaction was accounted for under the acquisition method of accounting. Accordingly, the results of NeuroNexus operations have been included in our Greatbatch Medical segment from the date of acquisition. For 2012, NeuroNexus added approximately $0.2 million to revenue and decreased net income by $0.2 million. Total consideration includes cash payments to shareholders of $10.0 million, NeuroNexus debt repaid at closing by Greatbatch of $1.5 million, NeuroNexus transaction expenses paid at closing by Greatbatch of $0.2 million and potential payments of up to $2 million through 2015 that are contingent upon the achievement of certain financial and development-based milestones which had an estimated fair value of $1.5 million as of the acquisition date.
The cost of the acquisition was preliminarily allocated to the assets acquired and liabilities assumed from NeuroNexus based on their fair values as of the close of the acquisition, with the amount exceeding the fair value of the net assets acquired being recorded as goodwill. The value assigned to certain assets and liabilities are preliminary and are subject to adjustment as additional information is obtained, including, but not limited to, the finalization of our intangible asset valuation, working capital adjustment as defined in the purchase agreement and pre-acquisition tax positions. The valuation is expected to be finalized in 2012. When the valuation is finalized, any changes to the preliminary valuation of assets acquired or liabilities assumed may result in material adjustments to the fair value of the intangible assets acquired, as well as goodwill. The following table summarizes the preliminary allocation of the NeuroNexus purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):
Assets acquired | ||||||
Current assets | $ | 618 | ||||
Property, plant and equipment | 35 | |||||
Amortizing intangible assets | 2,927 | |||||
Indefinite-lived intangible assets | 540 | |||||
Goodwill | 8,875 | |||||
Other assets | 1,576 | |||||
Total assets acquired | 14,571 | |||||
Liabilities assumed | ||||||
Current liabilities | 420 | |||||
Deferred income taxes | 940 | |||||
Total liabilities assumed | 1,360 | |||||
$ | 13,211 |
The preliminary fair values of the assets acquired were determined using one of three valuation approaches: market, income and cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations.
The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, product life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions.
Current assets and liabilities - The fair value of current assets and liabilities was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities.
Intangible assets - The purchase price was allocated to intangible assets as follows (dollars in thousands):
Weighted | Weighted | Weighted | ||||||||
Fair | Average | Average | Average | |||||||
Value | Amortization | Useful | Discount | |||||||
Amortizing Intangible Assets | Assigned | Period (Years) | Life (Years) | Rate | ||||||
Technology and patents | $ | 1,058 | 6 | 10 | 14% | |||||
Customer lists | 1,869 | 7 | 15 | 13% | ||||||
$ | 2,927 | 7 | 13 | 13% | ||||||
Indefinite-lived Intangible Assets | ||||||||||
In-process research and development | $ | 540 | N/A | 12 | 26% |
The weighted average amortization period is less than the estimated useful life due to the Company using an accelerated amortization method, which approximates the projected cash flows used to determine the fair value of those intangible assets.
Technology and patents - Technology and patents consist of technical processes, patented and unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by NeuroNexus and that will be leveraged in current and future products. The fair value of technology and patents acquired was determined utilizing the relief from royalty method, a form of the income approach, with royalty rates that ranged from 2% to 6%. The Company determined that the estimated useful life of the technology and patents is approximately 10 years. This life is based upon management's estimate of the product life cycle associated with technology and patents before they will be replaced by new technologies.
Customer lists – Customer lists represent the estimated fair value of non-contractual customer relationships NeuroNexus has as of the acquisition date. The primary customers of NeuroNexus include numerous scientists and researchers from various geographic locations around the world. These relationships were valued separately from goodwill at the amount which an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The Company determined that the estimated useful life of the existing customer lists is approximately 15 years. This life was based upon historical customer attrition as well as management's understanding of the industry and product life cycles.
In-process research and development (“IPR&D”) – IPR&D represents research projects which are expected to generate cash flows but have not yet reached technological feasibility. The primary basis for determining the technological feasibility of these projects is whether or not regulatory approval has been obtained. We classify IPR&D acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated projects. Upon completion, we would determine the useful life of the IPR&D and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we would write-off the remaining carrying amount of the associated IPR&D. We will test the IPR&D acquired for impairment at least annually, and more frequently if events or changes in circumstances indicate that the assets may be impaired. The impairment test consists of a comparison of the fair value of the intangible assets with their carrying amount. If the carrying amount exceeds its fair value, we would record an impairment loss in an amount equal to the excess. We used the income approach to determine the fair value of the IPR&D acquired. In arriving at the value of the IPR&D, we considered, among other factors: the projects' stage of completion; the complexity of the work to be completed as of the acquisition date; the projected costs to complete the projects; the contribution of other acquired assets; and the estimated useful life of the technology. We applied a market-participant risk-adjusted discount rate to arrive at a present value as of the date of acquisition.
The value assigned to IPR&D related to the development of micro-electrodes for deep brain mapping and electrocorticography, and is expected to be commercialized by 2014. For purposes of valuing the IPR&D, the Company estimated total costs to complete the projects to be approximately $1.5 million. If the projects are not successful or completed in a timely manner, we may not realize the financial benefits expected for these projects.
Goodwill - The excess of the purchase price over the fair value of net tangible and intangible assets acquired of $8.9 million was allocated to goodwill. Various factors contributed to the establishment of goodwill, including: the value of NeuroNexus's highly trained assembled work force and management team; the incremental value that NeuroNexus's technology will bring to the Company's neuromodulation platform currently in development; and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the NeuroNexus acquisition was allocated to the Greatbatch Medical business segment and is not deductible for tax purposes.
Micro Power Electronics, Inc.
On December 15, 2011, Electrochem acquired all of the outstanding common and preferred stock of Micro Power Electronics, Inc. (“Micro Power”) headquartered in Beaverton, OR. Micro Power is a leading supplier of custom battery solutions, serving the portable medical, military and handheld automatic identification and data collection markets. The aggregate purchase price of Micro Power was $71.8 million, which the Company funded with cash on hand and $45 million borrowed under its revolving credit facility. Total assets acquired from Micro Power were $88.2 million, of which $60.7 million were intangible assets.
This transaction was accounted for under the acquisition method of accounting. Accordingly, the results of Micro Power's operations were included in the consolidated financial statements from the date of acquisition and the cost of the acquisition was preliminarily allocated to the assets acquired and liabilities assumed from Micro Power based on their fair values as of the close of the acquisition, with the amount exceeding the fair value of net assets acquired being recorded as goodwill. The value assigned to certain assets and liabilities are preliminary and are subject to adjustment as additional information is obtained, including, but not limited to, the finalization of our pre-acquisition tax positions. The valuation will be finalized in 2012. During the first quarter of 2012 the Company completed its branding analysis related to the Micro Power tradename and settled the contractual working capital adjustment in accordance with the purchase agreement. As a result, the Company reduced the fair value recorded for the Micro Power trade name by $0.4 million and adjusted the related deferred tax liability by $0.1 million. The net result was an increase to goodwill of $0.3 million. The impact of these adjustments, individually and in the aggregate, was not considered material to reflect as a retrospective adjustment of the historical financial statements.
Pro Forma Results (Unaudited)
The following unaudited pro forma information presents the consolidated results of operations of the Company, NeuroNexus and Micro Power as if those acquisitions occurred as of the beginning of fiscal years 2011 (NeuroNexus) and 2010 (Micro Power) (in thousands, except per share amounts):
Three Months Ended | ||||||||
March 30, | April 1, | |||||||
2012 | 2011 | |||||||
Sales | $ | 159,543 | $ | 164,555 | ||||
Net income | 4,293 | 11,201 | ||||||
Earnings per share: | ||||||||
Basic | $ | 0.18 | $ | 0.48 | ||||
Diluted | $ | 0.18 | $ | 0.47 |
The unaudited pro forma information presents the combined operating results of Greatbatch, NeuroNexus and Micro Power, with the results prior to the acquisition date adjusted to include the pro forma impact of the amortization of acquired intangible assets based on the purchase price allocations, the adjustment to interest expense reflecting the amount borrowed in connection with the acquisitions at Greatbatch's interest rate, and the impact of income taxes on the pro forma adjustments utilizing the applicable statutory tax rate. The unaudited pro forma consolidated basic and diluted earnings per share calculations are based on the consolidated basic and diluted weighted average shares of Greatbatch.
The unaudited pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings, and any related integration costs. Certain cost savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These pro forma results do not purport to be indicative of the results that would have been obtained, or to be a projection of results that may be obtained in the future.
|
3. SUPPLEMENTAL CASH FLOW INFORMATION
Three Months Ended | ||||||||
March 30, | April 1, | |||||||
(in thousands) | 2012 | 2011 | ||||||
Noncash investing and financing activities : | ||||||||
Unrealized gain on cash flow hedges, net | $ | 525 | $ | 270 | ||||
Common stock contributed to 401(k) Plan | 4,793 | - | ||||||
Property, plant and equipment purchases included | ||||||||
in accounts payable | 6,002 | (191) | ||||||
Cash paid during the period for: | ||||||||
Interest | $ | 429 | $ | 424 | ||||
Income taxes | 547 | 118 | ||||||
Acquisition of noncash assets | $ | 14,379 | $ | 125 | ||||
Liabilities assumed | 1,226 | - |
|
4. INVENTORIES
Inventories are comprised of the following (in thousands): | |||||||
As of | |||||||
March 30, | December 30, | ||||||
2012 | 2011 | ||||||
Raw materials | $ | 50,396 | $ | 49,773 | |||
Work-in-process | 38,571 | 36,603 | |||||
Finished goods | 23,483 | 23,537 | |||||
Total | $ | 112,450 | $ | 109,913 |
|
5. INTANGIBLE ASSETS
Amortizing intangible assets are comprised of the following (in thousands): | |||||||||||||
At | March 30, 2012 | Gross Carrying Amount | Accumulated Amortization | Foreign Currency Translation | Net Carrying Amount | ||||||||
Purchased technology and patents | $ | 98,382 | $ | (56,085) | $ | 1,164 | $ | 43,461 | |||||
Customer lists | 68,257 | (15,480) | 2,358 | 55,135 | |||||||||
Other | 4,812 | (4,109) | 776 | 1,479 | |||||||||
Total amortizing intangible assets | $ | 171,451 | $ | (75,674) | $ | 4,298 | $ | 100,075 | |||||
At | December 30, 2011 | ||||||||||||
Purchased technology and patents | $ | 97,324 | $ | (54,054) | $ | 842 | $ | 44,112 | |||||
Customer lists | 66,388 | (14,009) | 1,807 | 54,186 | |||||||||
Other | 5,174 | (4,019) | 805 | 1,960 | |||||||||
Total amortizing intangible assets | $ | 168,886 | $ | (72,082) | $ | 3,454 | $ | 100,258 |
Aggregate intangible asset amortization expense is comprised of the following (in thousands): | ||||||||
Three Months Ended | ||||||||
March 30, | April 1, | |||||||
2012 | 2011 | |||||||
Cost of sales | $ | 1,895 | $ | 1,501 | ||||
Selling, general and administrative expenses | 1,561 | 953 | ||||||
Research, development and engineering costs | 136 | - | ||||||
Total intangible asset amortization expense | $ | 3,592 | $ | 2,454 |
Estimated future intangible asset amortization expense based upon the current carrying value is as follows (in thousands): | ||||
Estimated | ||||
Amortization | ||||
Expense | ||||
Remainder of 2012 | $ | 10,836 | ||
2013 | 13,698 | |||
2014 | 13,698 | |||
2015 | 12,595 | |||
2016 | 10,280 | |||
Thereafter | 38,968 | |||
$ | 100,075 |
The change in indefinite-lived intangible assets is as follows (in thousands): | ||||||||||
Trademarks and Tradenames | IPR&D | Total | ||||||||
At | December 30, 2011 | $ | 20,288 | $ | - | $ | 20,288 | |||
Indefinite-lived assets acquired | - | 540 | 540 | |||||||
At | March 30, 2012 | $ | 20,288 | $ | 540 | $ | 20,828 | |||
The change in goodwill is as follows (in thousands): | ||||||||||
Greatbatch Medical | Electrochem | Total | ||||||||
At | December 30, 2011 | $ | 297,232 | $ | 41,421 | $ | 338,653 | |||
Goodwill acquired | 8,875 | 331 | 9,206 | |||||||
Foreign currency translation | 1,612 | - | 1,612 | |||||||
At | March 30, 2012 | $ | 307,719 | $ | 41,752 | $ | 349,471 |
|
6. DEBT
Long-term debt is comprised of the following (in thousands): | |||||||
At | |||||||
March 30, | December 30, | ||||||
2012 | 2011 | ||||||
Revolving line of credit | $ | 55,000 | $ | 55,000 | |||
2.25% convertible subordinated notes, due 2013 | 197,782 | 197,782 | |||||
Unamortized discount | (14,143) | (16,832) | |||||
Total long-term debt | $ | 238,639 | $ | 235,950 |
Revolving Line of Credit –The Company has a revolving credit facility (the “Credit Facility”), which provides a $400 million secured revolving credit facility, and can be increased to $600 million upon the Company's request and approval by a majority of the lenders. The Credit Facility also contains a $15 million letter of credit subfacility and a $15 million swingline subfacility. The Credit Facility has a maturity date of June 24, 2016; provided, however, if CSN (defined below) is not repaid in full, modified or refinanced before March 1, 2013, the maturity date of the Credit Facility will be March 1, 2013.
The Credit Facility is secured by the Company's non-realty assets including cash, accounts receivable and inventories. Interest rates under the Credit Facility are, at the Company's option either at: (i) the higher of (a) the prime rate and (b) the federal funds rate plus 0.5%, plus the applicable margin, which ranges between 0.0% and 1.0%, based on the Company's total leverage ratio or (ii) the applicable LIBOR rate plus the applicable margin, which ranges between 1.5% and 3.0%, based on the Company's total leverage ratio. Loans under the swingline subfacility will bear interest at the higher of (a) the prime rate and (b) the federal funds rate plus 0.5%, plus the applicable margin, which ranges between 0.0% and 1.0%, based on the Company's total leverage ratio. The Company is also required to pay a commitment fee which, varies between 0.175% and 0.25% depending on the Company's total leverage ratio.
The Credit Facility contains limitations on the incurrence of indebtedness, liens and licensing of intellectual property, investments and certain payments. The Credit Facility permits the Company to engage in the following activities up to an aggregate amount of $250 million: 1) engage in permitted acquisitions in the aggregate not to exceed $250 million; 2) make other investments in the aggregate not to exceed $60 million; 3) make stock repurchases not to exceed $60 million in the aggregate; and 4) retire up to $198 million of Greatbatch, Inc.'s CSN. At any time that the total leverage ratio of the Company for the two most recently ended fiscal quarters is less than 2.75 to 1.0, the Company may make an election to reset each of the amounts specified above. Additionally, these limitations can be waived upon the Company's request and approval of a majority of the lenders. As of March 30, 2012, the Company had available to it the full amount of the above limits except for the permitted acquisitions and CSN retirement limits, which is $165 million due to the Micro Power and NeuroNexus acquisitions.
The Credit Facility requires the Company to maintain a rolling four quarter ratio of adjusted EBITDA to interest expense of at least 3.0 to 1.0, and a total leverage ratio of not greater than 4.0 to 1.0. The calculation of adjusted EBITDA and total leverage ratio excludes non-cash charges, extraordinary, unusual, or non-recurring expenses or losses, non-cash stock-based compensation, and non-recurring expenses or charges incurred in connection with permitted acquisitions. As of March 30, 2012, the Company was in compliance with all covenants.
The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable.
The weighted average interest rate on borrowings under the Credit Facility as of March 30, 2012, was 2.13%. As of March 30, 2012, the Company had $345 million of borrowing capacity available under the Credit Facility. This borrowing capacity may vary from period to period based upon the debt levels of the Company as well as the level of EBITDA, which impacts the covenant calculations as described above.
Interest Rate Swaps –In 2008, the Company entered into three receive floating-pay fixed interest rate swaps indexed to the six-month LIBOR rate, in order to hedge against potential changes in cash flows on the Company's outstanding debt, which was also indexed to the six-month LIBOR rate. As of March 30, 2012, none of these interest rate swaps remain outstanding. The receive variable leg of the interest rate swaps and the variable rate paid on the debt had the same rate of interest, excluding the credit spread, and reset and paid interest on the same dates. The Company accounted for these interest rate swaps as cash flow hedges. No portion of the change in fair value of the interest rate swaps during 2011 was considered ineffective. The amount recorded as Interest Expense related to the interest rate swaps was $0.2 million for the first quarter of 2011.
Convertible Subordinated Notes – In March 2007, the Company completed a private placement of $197.8 million of 2.25% convertible subordinated notes, due June 15, 2013 (“CSN”). CSN bear interest at 2.25% per annum, payable semi-annually, are due on June 15, 2013, and were issued at a 5% discount. The holders may convert the notes into shares of the Company's common stock at a conversion price of $34.70 per share, which is equivalent to a conversion ratio of 28.8219 shares per $1,000 of principal. The conversion price and the conversion ratio will adjust automatically upon certain changes to the Company's capitalization. The fair value of CSN as of March 30, 2012 was approximately $198 million and is based on recent sales prices.
The effective interest rate of CSN, which takes into consideration the amortization of the discount and deferred fees related to the issuance of these notes, is approximately 8.5%. The discount on CSN is being amortized to the maturity date of the convertible notes utilizing the effective interest method. As of March 30, 2012, the carrying amount of the discount related to the CSN conversion option was $12.0 million. As of March 30, 2012, the if-converted value of the CSN notes does not exceed their principal amount as the Company's closing stock price of $24.52 per share did not exceed the conversion price of $34.70 per share.
The contractual interest and discount amortization for CSN were as follows (in thousands): | ||||||||
Three Months Ended | ||||||||
March 30, | April 1, | |||||||
2012 | 2011 | |||||||
Contractual interest | $ | 1,113 | $ | 1,113 | ||||
Discount amortization | 2,689 | 2,516 |
The notes are convertible at the option of the holders at such time as: (i) the closing price of the Company's common stock exceeds 150% of the conversion price of the notes for 20 out of 30 consecutive trading days; (ii) the trading price per $1,000 of principal is less than 98% of the product of the closing sale price of common stock for each day during any five consecutive trading day period and the conversion rate per $1,000 of principal; (iii) the notes have been called for redemption; (iv) the Company distributes to all holders of common stock rights or warrants entitling them to purchase additional shares of common stock at less than the average closing price of common stock for the ten trading days immediately preceding the announcement of the distribution; (v) the Company distributes to all holders of common stock any form of dividend which has a per share value exceeding 5% of the price of the common stock on the day prior to such date of distribution; (vi) the Company effects a consolidation, merger, share exchange or sale of assets pursuant to which its common stock is converted to cash or other property; (vii) the occurrence of the period beginning 60 days prior to but excluding June 15, 2013; and (viii) certain fundamental changes, as defined in the indenture governing the notes, occur or are approved by the Board of Directors.
Conversions in connection with corporate transactions that constitute a fundamental change require the Company to pay a premium make-whole amount, based upon a predetermined table as set forth in the indenture, whereby the conversion ratio on the notes may be increased by up to 7.0 shares per $1,000 of principal. The premium make-whole amount will be paid in shares of common stock upon any such conversion, subject to the net share settlement feature of the notes described below.
CSN contains a net share settlement feature that requires the Company to pay cash for each $1,000 of principal to be converted. Any amounts in excess of $1,000 will be settled in shares of the Company's common stock, or at the Company's option, cash. The Company has a one-time irrevocable election to pay the holders in shares of its common stock, which it currently does not plan to exercise.
CSN are redeemable by the Company at any time on or after June 20, 2012, or at the option of a holder, upon the occurrence of certain fundamental changes, as defined in the indenture, to the Company. The notes are subordinated in right of payment to all of the Company's senior indebtedness and effectively subordinated to all debts and other liabilities of the Company's subsidiaries.
Deferred Financing Fees - The change in deferred financing fees is as follows (in thousands):
At | December 30, 2011 | $ | 3,149 | |
Amortization during the period | (267) | |||
At | March 30, 2012 | $ | 2,882 |
|
7. DEFINED BENEFIT PLANS
The Company is required to provide its employees located in Switzerland, Mexico and France certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit plan provided to the Company's employees located in Switzerland is a funded contributory plan while the plans that provide benefits to the Company's employees located in Mexico and France are unfunded and noncontributory. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees.
The change in net defined benefit plan liability is as follows (in thousands): | |||||
At | December 30, 2011 | $ | 5,569 | ||
Net defined benefit cost | 312 | ||||
Benefit payments | (299) | ||||
Foreign currency translation | 199 | ||||
At | March 30, 2012 | $ | 5,781 |
Net defined benefit cost is comprised of the following (in thousands): | ||||||
Three Months Ended | ||||||
March 30, | April 1, | |||||
2012 | 2011 | |||||
Service cost | $ | 285 | $ | 257 | ||
Interest cost | 104 | 111 | ||||
Amortization of net loss and prior service cost | 31 | 19 | ||||
Expected return on plan assets | (108) | (110) | ||||
Net defined benefit cost | $ | 312 | $ | 277 | ||
|
8. STOCK-BASED COMPENSATION
The components and classification of stock-based compensation expense were as follows (in thousands):
Three Months Ended | ||||||
March 30, | April 1, | |||||
2012 | 2011 | |||||
Stock options | $ | 678 | $ | 534 | ||
Restricted stock and units | 1,509 | 993 | ||||
401(k) stock contribution | 0 | 1,220 | ||||
Total stock-based compensation expense | $ | 2,187 | $ | 2,747 | ||
Three Months Ended | ||||||
March 30, | April 1, | |||||
2012 | 2011 | |||||
Cost of sales | $ | 263 | $ | 1,005 | ||
Selling, general and administrative | 1,817 | 1,489 | ||||
Research, development and engineering | 107 | 253 | ||||
Total stock-based compensation expense | $ | 2,187 | $ | 2,747 |
The weighted average fair value and assumptions used to value stock options granted are as follows: | |||||||
Three Months Ended | |||||||
March 30, | April 1, | ||||||
2012 | 2011 | ||||||
Weighted average fair value | $ | 8.18 | $ | 9.42 | |||
Risk-free interest rate | 0.83% | 2.04% | |||||
Expected volatility | 40% | 40% | |||||
Expected life (in years) | 5 | 5 | |||||
Expected dividend yield | 0% | 0% |
The following table summarizes time-vested stock option activity: | |||||||||||||||
Number of Time-Vested Stock Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (In Years) | Aggregate Intrinsic Value (In Millions) | ||||||||||||
Outstanding at | December 30, 2011 | 1,558,771 | $ | 23.42 | |||||||||||
Granted | 348,212 | 22.14 | |||||||||||||
Exercised | (6,450) | 21.38 | |||||||||||||
Forfeited or expired | (34,090) | 24.10 | |||||||||||||
Outstanding at | March 30, 2012 | 1,866,443 | $ | 23.18 | 6.6 | $ | 4.0 | ||||||||
Exercisable at | March 30, 2012 | 1,294,612 | $ | 23.38 | 5.5 | $ | 2.9 |
The following table summarizes performance-vested stock option activity: | |||||||||||||||
Number of Performance-Vested Stock Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (In Years) | Aggregate Intrinsic Value (In Millions) | ||||||||||||
Outstanding at | December 30, 2011 | 478,364 | $ | 24.44 | |||||||||||
Exercised | (3,873) | 22.19 | |||||||||||||
Forfeited or expired | (177,733) | 26.49 | |||||||||||||
Outstanding at | March 30, 2012 | 296,758 | $ | 23.24 | 5.1 | $ | 0.5 | ||||||||
Exercisable at | March 30, 2012 | 296,758 | $ | 23.24 | 5.1 | $ | 0.5 |
The following table summarizes time-vested restricted stock and unit activity: | |||||||||
Time-Vested Activity | Weighted Average Fair Value | ||||||||
Nonvested at | December 30, 2011 | 69,942 | $ | 22.69 | |||||
Granted | 79,805 | 23.43 | |||||||
Vested | (12,692) | 21.74 | |||||||
Forfeited or expired | (1,465) | 22.55 | |||||||
Nonvested at | March 30, 2012 | 135,590 | $ | 23.21 |
The following table summarizes performance-vested restricted stock and unit activity: | |||||||||
Performance-Vested Activity | Weighted Average Fair Value | ||||||||
Nonvested at | December 30, 2011 | 529,743 | $ | 16.68 | |||||
Granted | 302,116 | 15.30 | |||||||
Vested | (7,000) | 24.64 | |||||||
Forfeited or expired | (38,413) | 15.74 | |||||||
Nonvested at | March 30, 2012 | 786,446 | $ | 16.13 |
|
9. OTHER OPERATING EXPENSES, NET
Other Operating Expenses, Net is comprised of the following (in thousands): | |||||||
Three Months Ended | |||||||
March 30, | April 1, | ||||||
2012 | 2011 | ||||||
Orthopaedic facility optimization(a) | $ | 344 | $ | 239 | |||
Medical device facility optimization(b) | 329 | - | |||||
ERP system upgrade(c) | 895 | - | |||||
Integration costs(d) | 943 | - | |||||
Asset dispositions and other(e) | 234 | (72) | |||||
$ | 2,745 | $ | 167 |
(a) Orthopaedic facility optimization. In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities and reduce dependence on outside suppliers. This initiative was completed in 2011.
In 2011, the Company began construction on an 80,000 square foot manufacturing facility in Allen County, IN and will transfer the manufacturing operations currently being performed at its Columbia City, IN location into this new facility. This facility is expected to be completed by mid-2012.
In 2011, the Company also initiated a multi-faceted plan to further enhance, optimize and leverage the Company's Orthopaedics manufacturing infrastructure. This plan includes the transferring of production of certain Orthopaedic product lines to other lower cost manufacturing facilities and the consolidation of the Company's Switzerland Orthopaedic operations. These initiatives are expected to be completed over the next two years.
The total capital investment expected to be incurred for these initiatives is between $50 million and $60 million, of which $25 million has been incurred. Total expense expected to be incurred for these initiatives is between $10 million and $15 million, of which $1 million has been incurred. All expenses will be recorded within the Greatbatch Medical segment and are expected to include the following:
The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands): | |||||||||||||||||||
Severance and Retention | Production Inefficiencies, Moving and Revalidation | Accelerated Depreciation/Asset Write-offs | Personnel | Other | Total | ||||||||||||||
At | December 30, 2011 | $ | - | $ | - | $ | - | $ | - | $ | - | $ | - | ||||||
Restructuring charges | - | 53 | - | 185 | 106 | 344 | |||||||||||||
Cash payments | - | (53) | - | (185) | (106) | (344) | |||||||||||||
At | March 30, 2012 | $ | 0 | $ | 0 | $ | 0 | $ | 0 | $ | 0 | $ | 0 |
(b) Medical device facility optimization. Near the end of 2011, the Company initiated plans to optimize and expand its manufacturing infrastructure in order to support its medical device strategy. This will include the transfer of certain product lines to create additional capacity for the manufacture of medical devices, expansion of two existing facilities, as well as the purchase of equipment to enable the production of medical devices. These initiatives are expected to be completed over the next two to three years. Total capital investment under these initiatives is expected to be between $15 million to $20 million of which approximately $1 million has been incurred to date. Total expenses expected to be incurred on these projects is between $2 million to $3 million of which $0.3 million has been incurred to date. All expenses will be recorded within the Greatbatch Medical segment and are expected to include the following:
The change in accrued liabilities related to the medical device facility optimization is as follows (in thousands): | |||||||||||||||||||
Production Inefficiencies, Moving and Revalidation | Personnel | Other | Total | ||||||||||||||||
At | December 30, 2011 | $ | - | $ | - | $ | - | $ | - | ||||||||||
Restructuring charges | 116 | 45 | 168 | 329 | |||||||||||||||
Cash payments | (116) | (45) | (168) | (329) | |||||||||||||||
At | March 30, 2012 | $ | 0 | $ | 0 | $ | 0 | $ | 0 |
(c) ERP system upgrade. In 2011, the Company initiated plans to upgrade its existing global ERP system. This initiative is expected to be completed over the next two years. Total capital investment to be incurred under this initiative is approximately $4 million to $5 million of which approximately $0.9 million has been incurred to date. Total expenses expected to be incurred on this initiative is between $5 million to $7 million of which $0.9 million has been incurred to date. Expenses related to this initiative will be recorded within the applicable segment and corporate cost centers that the expenditures relate to and include the following:
The change in accrued liabilities related to the ERP system upgrade is as follows (in thousands): | ||||||||||||||||
Consulting Costs | Training Costs | Accelerated Depreciation/Asset Write-offs | Total | |||||||||||||
At | December 30, 2011 | $ | - | $ | - | $ | - | $ | - | |||||||
Restructuring charges | 159 | - | 736 | 895 | ||||||||||||
Write-offs | - | - | (736) | (736) | ||||||||||||
Cash payments | (159) | - | - | (159) | ||||||||||||
At | March 30, 2012 | $ | 0 | $ | 0 | $ | 0 | $ | 0 |
(d) Integration costs. During 2012, the Company incurred costs related to the integration of Micro Power and NeuroNexus. These expenses were primarily for retention bonuses, travel costs in connection with integration efforts, and severance, which will not be required or incurred after the integrations are completed.
(e) Asset dispositions, severance and other. During 2012 and 2011, the Company recorded write-downs (gains) in connection with various asset disposals, net of insurance proceeds received, if any.
|
10. INCOME TAXES
The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of this effective tax rate due to several factors, including changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business acquisitions, settlements with taxing authorities and foreign currency fluctuations.
During the first quarter of 2012, the balance of unrecognized tax benefits decreased by $0.5 million as a result of the settlement of IRS audits for 2009 and 2010. Approximately $1.0 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate (net of federal benefit on state issues), if recognized. It is reasonably possible that a reduction of up to $0.3 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of the expiration of applicable statutes of limitation.
|
11. COMMITMENTS AND CONTINGENCIES
Litigation – The Company is a party to various legal actions arising in the normal course of business. While the Company does not believe that the ultimate resolution of any such pending actions will have a material effect on its results of operations, financial position, or cash flows, litigation is subject to inherent uncertainties. If an unfavorable ruling were to occur, there exists the possibility of a material impact in the period in which the ruling occurs.
Product Warranties – The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company accrues its estimated exposure to warranty claims based upon recent historical experience and other specific information as it becomes available.
The change in aggregate product warranty liability for the quarter is as follows (in thousands): | |||||
At | December 30, 2011 | $ | 2,013 | ||
Additions to warranty reserve | 50 | ||||
Warranty claims paid | (178) | ||||
Foreign currency effect | 13 | ||||
At | March 30, 2012 | $ | 1,898 |
Purchase Commitments – Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Our purchase orders are normally based on our current manufacturing needs and are fulfilled by our vendors within short time horizons. We enter into blanket orders with vendors that have preferred pricing and terms, however these orders are normally cancelable by us without penalty. As of March 30, 2012, the total contractual obligation related to such expenditures is approximately $32.5 million and will be funded by existing cash and cash equivalents, cash flow from operations, or the Credit Facility. We also enter into contracts for outsourced services; however, the obligations under these contracts were not significant and the contracts generally contain clauses allowing for cancellation without significant penalty.
Operating Leases – The Company is a party to various operating lease agreements for buildings, equipment and software. Minimum future annual operating lease payments are as follows (in thousands):
Remainder of 2012 | $ | 2,994 | ||
2013 | 3,445 | |||
2014 | 3,478 | |||
2015 | 3,117 | |||
2016 | 2,856 | |||
Thereafter | 2,895 | |||
Total estimated operating lease expense | $ | 18,785 |
Foreign Currency Contracts – The Company has entered into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with the operations at its Tijuana, Mexico facility. The impact to the Company's results of operations from these forward contracts was as follows (in thousands):
Three Months Ended | ||||||
March 30, | April 1, | |||||
2012 | 2011 | |||||
Increase (reduction) in Cost of Sales | $ | 78 | $ | (143) | ||
Ineffective portion of change in fair value | - | - |
Information regarding the Company's outstanding foreign currency contracts as of March 30, 2012 is as follows (dollars in thousands): | |||||||||||||||
Aggregate | |||||||||||||||
Type of | Notional | Start | End | Fair | Balance Sheet | ||||||||||
Instrument | Hedge | Amount | Date | Date | Pesos/$ | Value | Location | ||||||||
FX Contract | Cash flow | $ | 4,500 | Jan-12 | Dec-12 | 13.0354 | $ | 18 | Current Assets | ||||||
FX Contract | Cash flow | 3,150 | Jan-12 | Dec-12 | 14.0287 | 252 | Current Assets |
Self-Insured Medical Plan – The Company self-funds the medical insurance coverage provided to its U.S. based employees. The risk to the Company is being limited through the use of stop loss insurance, which has an annual deductible of $0.2 million per covered participant. The maximum aggregate loss (the sum of all claims under the $0.2 million deductible) is limited to $13.5 million with a maximum benefit of $1.0 million. As of March 30, 2012, the Company has $1.8 million accrued related to the self-insurance of its medical plan, which is recorded in Accrued Expenses in the Condensed Consolidated Balance Sheet, and is primarily based upon claim history.
|
13. ACCUMULATED OTHER COMPREHENSIVE INCOME
Accumulated Other Comprehensive Income is comprised of the following (in thousands): | ||||||||||||||||||
Defined Benefit Plan Liability | Cash Flow Hedges | Foreign Currency Translation Adjustment | Total Pre-Tax Amount | Tax | Net-of-Tax Amount | |||||||||||||
At | December 30, 2011 | $ | (2,660) | $ | (538) | $ | 11,526 | $ | 8,328 | $ | 601 | $ | 8,929 | |||||
Unrealized gain on cash flow hedges | - | 886 | - | 886 | (310) | 576 | ||||||||||||
Realized gain on cash flow hedges | - | (78) | - | (78) | 27 | (51) | ||||||||||||
Foreign currency translation gain | - | - | 4,038 | 4,038 | - | 4,038 | ||||||||||||
At | March 30, 2012 | $ | (2,660) | $ | 270 | $ | 15,564 | $ | 13,174 | $ | 318 | $ | 13,492 |
|
14. FAIR VALUE MEASUREMENTS
Assets and Liabilities Measured at Fair Value on a Recurring Basis
Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and accrued contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis.
Foreign currency contracts - The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. In addition to the above, the Company receives fair value estimates from the foreign currency contract counterparty to verify the reasonableness of the Company's estimates. The Company's foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company's foreign currency contracts will be realized as cost of sales as the inventory, to which the contracts are hedging the cash flows to produce, is sold, and is expected to be realized within the next twelve months.
Accrued contingent consideration – In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. The Company re-measures this liability each reporting period and records changes in the fair value through the condensed consolidated statement of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable milestones.
The fair value of accrued contingent consideration recorded by the Company represents the estimated fair value of the contingent consideration the Company expects to pay to the former shareholders of NeuroNexus based upon the achievement of certain financial and development-based milestones. The fair value of the contingent consideration liability was estimated by discounting, to present value, contingent payments expected to be made. The Company used risk-adjusted discount rates ranging from 12 to 20 percent to derive the fair value of the expected obligations, which the Company believes is appropriate and representative of market participant assumptions. The Company's accrued contingent consideration is categorized in Level 3 of the fair value hierarchy.
The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis in the Company's Condensed Consolidated Balance Sheet as of March 30, 2012 (in thousands):
Fair Value Measurements Using | |||||||||||||
Quoted | |||||||||||||
Prices in | Significant | ||||||||||||
Active Markets | Other | Significant | |||||||||||
At | for Identical | Observable | Unobservable | ||||||||||
March 30, | Assets | Inputs | Inputs | ||||||||||
Description | 2012 | (Level 1) | (Level 2) | (Level 3) | |||||||||
Assets | |||||||||||||
Foreign currency contracts | $ | 270 | $ | 0 | $ | 270 | $ | 0 | |||||
Liabilities | |||||||||||||
Accrued contingent consideration | $ | 1,500 | $ | 0 | $ | - | $ | 1,500 |
Fair Value of Other Financial Instruments
Convertible subordinated notes - The fair value of the Company's convertible subordinated notes disclosed in Note 6 “Debt” was determined based upon recent third-party transactions for the Company's notes in an inactive market. The Company's convertible subordinated notes are valued for disclosure purposes utilizing Level 2 measurements of the fair value hierarchy.
|
15. BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION
The Company operates its business in two reportable segments – Greatbatch Medical and Electrochem Solutions (“Electrochem”). The Greatbatch Medical segment designs and manufactures medical devices and components for the cardiac rhythm management, neuromodulation, vascular access and orthopaedic markets. Additionally, Greatbatch Medical offers value-added assembly and design engineering services for products that incorporate Greatbatch Medical components. As a result of the strategy put in place over three years ago, Greatbatch Medical now offers its customers complete medical devices including design, development, manufacturing, regulatory submission and supporting worldwide distribution. This medical device strategy is being facilitated through the Company's QiG Group and leverages the component technology of Greatbatch Medical and Electrochem in the Company's core markets: cardiovascular, neuromodulation and orthopaedic. Once the QiG Group designs and develops a medical device, it is manufactured by Greatbatch Medical. The operating expenses (RD&E, SG&A) of the QiG Group are included within the Greatbatch Medical segment.
Electrochem designs, manufactures and distributes primary and rechargeable batteries, battery packs and wireless sensors for demanding applications in markets such as portable medical, energy, security, environmental monitoring and more.
The Company defines segment income from operations as sales less cost of sales including amortization and expenses attributable to segment-specific SG&A, RD&E expenses, and other operating expenses. Segment income also includes a portion of non-segment specific SG&A expenses based on allocations appropriate to the expense categories. The remaining unallocated operating and other expenses are primarily administrative corporate headquarters expenses and capital costs that are not allocated to reportable segments. Transactions between the two segments are not significant. An analysis and reconciliation of the Company's business segment, product line and geographic information to the respective information in the Condensed Consolidated Financial Statements follows. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped to (in thousands):
Three Months Ended | ||||||||
March 30, | April 1, | |||||||
Sales: | 2012 | 2011 | ||||||
Greatbatch Medical | ||||||||
CRM/Neuromodulation | $ | 75,135 | $ | 78,037 | ||||
Vascular Access | 11,636 | 10,474 | ||||||
Orthopaedic | 31,046 | 39,589 | ||||||
Total Greatbatch Medical | 117,817 | 128,100 | ||||||
Electrochem | 41,286 | 20,734 | ||||||
Total sales | $ | 159,103 | $ | 148,834 |
Three Months Ended | |||||||||
March 30, | April 1, | ||||||||
2012 | 2011 | ||||||||
Segment income from operations: | |||||||||
Greatbatch Medical | $ | 10,112 | $ | 18,947 | |||||
Electrochem | 4,471 | 4,407 | |||||||
Total segment income from operations | 14,583 | 23,354 | |||||||
Unallocated operating expenses | (3,385) | (5,388) | |||||||
Operating income as reported | 11,198 | 17,966 | |||||||
Unallocated other expense | (5,079) | (139) | |||||||
Income before provision for income taxes | $ | 6,119 | $ | 17,827 |
Three Months Ended | ||||||||||
March 30, | April 1, | |||||||||
2012 | 2011 | |||||||||
Sales by geographic area: | ||||||||||
United States | $ | 82,406 | $ | 65,201 | ||||||
Non-Domestic locations: | ||||||||||
Puerto Rico | 23,540 | 26,181 | ||||||||
Belgium | 15,338 | 18,969 | ||||||||
United Kingdom & Ireland | 12,357 | 10,493 | ||||||||
Rest of world | 25,462 | 27,990 | ||||||||
Total sales | $ | 159,103 | $ | 148,834 |
Four customers accounted for a significant portion of the Company’s sales as follows: | |||||||||
Three Months Ended | |||||||||
March 30, | April 1, | ||||||||
2012 | 2011 | ||||||||
Customer A | 20% | 22% | |||||||
Customer B | 13% | 17% | |||||||
Customer C | 10% | 14% | |||||||
Customer D | 7% | 7% | |||||||
50% | 60% |
Long-lived tangible assets by geographic area are as follows (in thousands): | |||||||
As of | |||||||
March 30, | December 30, | ||||||
2012 | 2011 | ||||||
United States | $ | 118,100 | $ | 113,693 | |||
Rest of world | 32,800 | 32,113 | |||||
Total | $ | 150,900 | $ | 145,806 |
|
16. IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS
In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission, Emerging Issues Task Force, American Institute of Certified Public Accountants or other authoritative accounting bodies to determine the potential impact they may have on the Company's Condensed Consolidated Financial Statements. Based upon this review, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company's Condensed Consolidated Financial Statements
In December 2011, the FASB issued Accounting Standards Update (“ASU”) No. 2011-11 “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities.” This ASU requires companies to provide information about trading in financial instruments and related derivatives in expanded disclosures, creates new disclosure requirements about the nature of an entity's rights of offset and related arrangements associated with its financial instruments and derivative instruments. The disclosure requirements are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods therein, with retrospective application required. When adopted, this ASU will not have a material impact on the Company's Condensed Consolidated Financial Statements as it only changes the disclosures surrounding the Company's offsetting assets and liabilities.
In September 2011, the FASB issued ASU No. 2011-08 “Intangibles—Goodwill and Other (Topic 350): Testing Goodwill for Impairment.” This ASU modifies the impairment test for goodwill intangibles. Under the revised guidance, entities performing their annual goodwill impairment test have the option of performing a qualitative assessment before calculating the fair value of the reporting unit (i.e., step 1 of the goodwill impairment test). If entities determine, on the basis of this qualitative assessment, that the fair value of the reporting unit is more likely than not (i.e., a likelihood of more than 50 percent) less than the carrying amount, the two-step goodwill impairment test would be required. ASU No. 2011-08 is effective for the Company beginning in fiscal year 2012. Early adoption is permitted. The Company did not adopt ASU No. 2011-08 for its 2011 annual goodwill impairment test. This ASU did not have a material impact on the Company's Condensed Consolidated Financial Statements.
In June 2011, the FASB issued ASU No. 2011-05 “Comprehensive Income (Topic 220): Presentation of Comprehensive Income.” This ASU provides companies two choices for presenting net income and comprehensive income: in a single continuous statement, or in two separate, but consecutive, statements. Presenting comprehensive income in the statement of equity is no longer an option. ASU No. 2011-05 is effective for the Company beginning in fiscal year 2012. In December 2011, the FASB issued ASU No. 2011-12 “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05,” which delays the effective date of certain provisions of ASU No. 2011-05 related to the presentation of reclassification adjustments out of accumulated other comprehensive income. During the first quarter of 2012, the Company adopted the provisions of ASU No. 2011-05 that were effective for 2012 and has elected to present net income and comprehensive income in a single continuous statement.
In May 2011, the FASB issued ASU No. 2011-04 “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs.” ASU No. 2011-04 establishes a global standard for applying fair value measurement. In addition to a few updates to the measurement guidance, ASU No. 2011-04 includes enhanced disclosure requirements. The most significant change for companies reporting under U.S. GAAP is an expansion of the disclosures required for “Level 3” measurements; that is, measurements based on unobservable inputs, such as a company's own data. This update is effective for the Company beginning in fiscal year 2012. ASU No. 2011-04 did not have a material impact on the Company's Condensed Consolidated Financial Statements.